NasdaqCM:CLDXBiotechs
Are Phase 2 Prurigo Nodularis Data And CFO Transition Altering The Investment Case For Celldex (CLDX)?
Earlier this month, Celldex Therapeutics reported Phase 2 topline results in prurigo nodularis and separately announced that long-serving Chief Financial Officer Sam Martin plans to retire around March 31, 2027, after supporting a transition to a new finance leader.
The combination of clinically relevant data in a difficult-to-treat skin condition and an orderly finance leadership transition gives investors fresh information on both Celldex’s pipeline progress and its organizational...